NeonMind Biosciences Inc.

10:22 AM EST - NeonMind Biosciences Inc. : Announced that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind's preclinical trial. The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind's proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time. NeonMind Biosciences Inc. shares C.NEON are trading down 1.64 percent at $0.30.